1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. North America Cancer Therapeutics Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. North America Cancer Therapeutics Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. North America Cancer Therapeutics Market Regional Analysis
6.2 North America Cancer Therapeutics Market Revenue 2021-2031 (US$ Million)
6.3 North America Cancer Therapeutics Market Forecast Analysis
7. North America Cancer Therapeutics Market Analysis – by Therapy Type
7.1 Chemotherapy
- 7.1.1 Overview
- 7.1.2 Chemotherapy: North America Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Targeted Therapy
- 7.2.1 Overview
- 7.2.2 Targeted Therapy: North America Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Radiation Therapy
- 7.3.1 Overview
- 7.3.2 Radiation Therapy: North America Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.4 Hormone Therapy
- 7.4.1 Overview
- 7.4.2 Hormone Therapy: North America Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.5 Other Therapy Types
- 7.5.1 Overview
- 7.5.2 Other Therapy Types: North America Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8. North America Cancer Therapeutics Market Analysis – by Indications
8.1 Blood Cancer
- 8.1.1 Overview
- 8.1.2 Blood Cancer: North America Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Lung Cancer
- 8.2.1 Overview
- 8.2.2 Lung Cancer: North America Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Breast Cancer
- 8.3.1 Overview
- 8.3.2 Breast Cancer: North America Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.4 Colorectal Cancer
- 8.4.1 Overview
- 8.4.2 Colorectal Cancer: North America Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.5 Prostate Cancer
- 8.5.1 Overview
- 8.5.2 Prostate Cancer: North America Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.6 Stomach Cancer
- 8.6.1 Overview
- 8.6.2 Stomach Cancer: North America Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.7 Cervical Cancer
- 8.7.1 Overview
- 8.7.2 Cervical Cancer: North America Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.8 Liver & Intrahepatic Bile Duct Cancer
- 8.8.1 Overview
- 8.8.2 Liver & Intrahepatic Bile Duct Cancer: North America Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.9 Thyroid Cancer
- 8.9.1 Overview
- 8.9.2 Thyroid Cancer: North America Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.10 Other Indications
- 8.10.1 Overview
- 8.10.2 Other Indications: North America Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
9. North America Cancer Therapeutics Market Analysis – by Distribution Channel
9.1 Hospital Pharmacies
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacies: North America Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.2 Retail Pharmacies
- 9.2.1 Overview
- 9.2.2 Retail Pharmacies: North America Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.3 Online Channel
- 9.3.1 Overview
- 9.3.2 Online Channel: North America Cancer Therapeutics Market – Revenue and Forecast, 2021-2031 (US$ Million)
10. North America Cancer Therapeutics Market – North America Analysis
10.1 Overview
10.2 North America
- 10.2.1 North America Cancer Therapeutics Market Breakdown, by Key
Country, 2025 and 2031 (%)
- 10.2.1.1 North America Cancer Therapeutics Market – Revenue and
Forecast Analysis – by Country
- 10.2.1.1 US:
North America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.1.1 US: North America Cancer Therapeutics Market Breakdown, by Therapy Type
- 10.2.1.1.2 US: North America Cancer Therapeutics Market Breakdown, by Indications
- 10.2.1.1.3 US: North America Cancer Therapeutics Market Breakdown, by Distribution Channel
- 10.2.1.2 Canada:
North America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.2.1 Canada: North America Cancer Therapeutics Market Breakdown, by Therapy Type
- 10.2.1.2.2 Canada: North America Cancer Therapeutics Market Breakdown, by Indications
- 10.2.1.2.3 Canada: North America Cancer Therapeutics Market Breakdown, by Distribution Channel
- 10.2.1.3 Mexico:
North America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.2.1.3.1 Mexico: North America Cancer Therapeutics Market Breakdown, by Therapy Type
- 10.2.1.3.2 Mexico: North America Cancer Therapeutics Market Breakdown, by Indications
- 10.2.1.3.3 Mexico: North America Cancer Therapeutics Market Breakdown, by Distribution Channel
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 Astellas Pharma Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Eli Lilly and Co
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Novartis AG
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Merck KGaA
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 AstraZeneca
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Pfizer Inc
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Hoffmann-La Roche Ltd
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Johnson & Johnson
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 AbbVie Inc
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Bristol-Myers Squibb Co
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations